UNS Short Interest, page-4

The market may not even have to wait for those ramp up revenues. A high profile equity position by a heavy hitter (e.g. one of those billionaire individuals that buys shares and a board seat in a biotech from time to time) or a supply agreement for a very high profile biologic. Those might do the trick to get the share price going. Obviously an equity position taken by a BD would set the cats among the pigeons as well. For example if the industry thinks wearable injectors has a big future then they will have to do something if Unilife continues to lock in Big Pharma.